Connect with us

Hi, what are you looking for?

News

DEA Removes Epidiolex From Controlled Substances List

The move will make it easier for patients and caretakers to access the medication.

DEA Removes Epidiolex From Controlled Substances List
Shutterstock

The U.S. Drug Enforcement Administration has removed the CBD pharmaceutical Epidiolex from the nation’s list of controlled substances, a move that should make it easier for patients to access the medication. Epidiolex is the only medication derived directly from cannabis that has been approved by the U.S. Food and Drug Administration for use in the United States.

The drug is a flavored oral solution with cannabidiol (CBD) that reduces seizures in children with epilepsy. The medicine, which is not psychoactive, also contains less than 0.1 percent THC. Epidiolex is produced by drug manufacturer GW Pharmaceutical at its facilities in the U.K.

After Epidiolex received FDA approval in June 2018, the drug was placed on Schedule V of the Controlled Substances Act (CSA). On Monday, GW was notified by the FDA that the drug is longer subject to the CSA, a change that goes into effect immediately.

“This notification from DEA fully establishes that EPIDIOLEX, the only CBD medicine approved by FDA, is no longer a controlled substance under the federal Controlled Substances Act,” said GW CEO Justin Gover in a press release.  “We would like to thank DEA for confirming the non-controlled status of this medicine. Importantly, the descheduling of EPIDIOLEX has the potential to further ease patient access to this important therapy for patients living with Lennox-Gastaut Syndrome and Dravet syndrome, two of the most debilitating forms of epilepsy.”

Easing Access For Patients

William Roark, the co-chair of the Pennsylvania Bar Association’s Medical Marijuana and Hemp Law Committee, said that removing Epidiolex from the CSA will make the drug more accessible to patients.

“It means doctors don’t have to go through the drug-monitoring program to make certain their patients don’t have a drug history,” he told the Philadelphia Inquirer. “And a parent will now be able to go from pharmacy to pharmacy rather than having one specific source.”

Although Epidiolex has only been approved by the FDA to treat Dravet syndrome and LGS, the so-called off-label use of drugs for other conditions is legal and a common practice with other medications. The price of the drug may be prohibitive for some patients that need it, however. In 2018, GW announced that the average annual cost of Epidiolex would come to about $32,500 per year, although most patients with health insurance would pay a fraction of that figure.

GW is also seeking approval from the FDA for Epidiolex to be used as a treatment for seizures associated with another disease, tuberous sclerosis complex.

3 Comments

3 Comments

  1. Avatar

    Joe Ballano

    April 7, 2020 at 7:13 am

    Congratulations GW!

  2. Avatar

    dan

    April 9, 2020 at 6:08 pm

    $32,500 per year?!!!!

  3. Avatar

    Ben Frame

    April 13, 2020 at 12:29 pm

    So what. It’s synthetic bullshit. Leave it to humans to think they know better than nature.

Leave a Reply

Your email address will not be published. Required fields are marked *

Advertisement

HT Newsletter

Subscribe for exclusive access to deals, free giveaways and more!

Thank you for subscribing.

Something went wrong.

Advertisement

You May Also Like

News

Attorney General William Barr issued a statement on Saturday that the DEA would be “deployed to support local efforts to enforce federal law.”

News

An infant born with Hypoxic Ischemic Encephalopathy will be treated with a cannabis-based medication.

Culture

Treating cancer with cannabis since infancy.

News

A cannabis lobbying group is asking the DEA to leave cannabis research to health experts.

Culture

The groundbreaking educational children's book is seeing a re-release fifteen years after its debut.

News

We extend our deepest and most heartfelt condolences to Charlotte's family and friends.

News

The children are prohibited from working in the plants.

News

The DEA seems to be advancing plans to expand medical marijuana research.

Do NOT follow this link or you will be banned from the site!